| Similar Articles |
|---|
 |
The Motley Fool
October 27, 2011
Sean Williams |
Idenix Pharmaceuticals Shares Popped: What You Need to Know Shares of biopharmaceutical company Idenix Pharmaceuticals jumped as much as 26% earlier in the trading session before paring the majority of its gains despite any company-specific news.   |
The Motley Fool
October 31, 2011
Brian Orelli |
Gunning for the Leaders Hepatitis C drugs take center stage. |
The Motley Fool
June 7, 2006
Stephen D. Simpson |
Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week. |
The Motley Fool
April 19, 2004
Charly Travers |
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry. |
The Motley Fool
January 9, 2012
Brian Orelli |
3 Reasons Hep C Premiums Might Not Last Careful what you wish for. |
The Motley Fool
November 18, 2011
Brian Orelli |
This Biotech Stock Rose for All the Wrong Reasons Achillion Pharmaceuticals announces it might get bought and shares jump by as much as 17% today in response to the report, although it's pulled back a little since then. |
The Motley Fool
January 9, 2012
Travis Hoium |
Idenix Pharmaceuticals Shares Jumped: What You Need to Know Shares of Idenix Pharmaceuticals got a positive diagnosis today and climbed 43% after the company released positive data for its hepatitis C drug. |
The Motley Fool
July 7, 2011
Brian Orelli |
J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo. |
The Motley Fool
December 16, 2011
Brian Orelli |
Safety (Still) Trumps Acquisitions in Hep C Pharmasset announced it was discontinuing all treatment arms in one of its phase 2b trials that contain the drug PSI-938. The drug candidate caused laboratory abnormalities in tests associated with liver function. |
Nurse Practitioner
December 2009
Gujral & Collantes |
Understanding Viral Hepatitis: A guide for primary care Recent advancements in the field of genomics and proteomics technology have given researchers and clinicians more insight on disease pathogenesis and helped create more tailored approaches to the treatment of these conditions. |
InternetNews
April 13, 2010 |
Google CEO Talks Web-Based Enterprise Apps Wrapping up a one-day summit for CIOs, Google's CEO explains why the company continues to venture beyond its core search services. |
American Family Physician
November 1, 2001
Thomas R. Riley |
Preventive Strategies in Chronic Liver Disease Chronic liver disease is the 10th leading cause of death in the United States. Preventive care can significantly reduce the progression of liver disease. Part I: Alcohol, Vaccines, Toxic Medications and Supplements, Diet and Exercise... |
The Motley Fool
November 29, 2011
Brian Orelli |
Every Biotech Is for Sale It just depends on the right price. |
